Which Hospital Is Best for Lung Cancer Surgery in 2026?

We do not designate or recommend a specific hospital. Under Korean medical law, agencies cannot advertise hospital names or institution-specific outcomes. Instead, we use your stage, biomarker test results, and lung function to assess surgical candidacy and outline the appropriate treatment approach in a written opinion.

Key Takeaways

• Under Korean medical law, recruitment agencies are prohibited from advertising specific hospitals or physicians, so we do not provide guidance by naming particular institutions.
• Korea's 5-year relative survival rate for lung cancer is 42.5%, a national aggregate figure (National Cancer Registration Statistics 2019-2023, National Cancer Center Korea), not the outcome of any single hospital.
• For stage 1-2 non-small cell lung cancer, thoracoscopic or robotic lobectomy is the standard surgery, and the patient's lung function must be sufficient to tolerate the resection.
• Surgical candidacy hinges primarily on whether mediastinal lymph node metastasis is present; PET-CT and brain MRI are used first to determine the stage.
• The remote review (pre-arrival review) fee is KRW 1,000,000 (about US$730), and this amount is deducted from treatment costs if the patient proceeds with treatment at the matched institution.

Why Can't You Tell Us the Hospital Name?

Korean medical law restricts recruitment agencies from advertising specific medical professionals or institutions. Figures like survival rates are national aggregates, not the results of any particular hospital. Korea's 5-year relative survival rate for lung cancer of 42.5% (National Cancer Registration Statistics 2019-2023) is 30 percentage points higher than the rate for patients diagnosed in 1993-1995, but this nationwide improvement reflects both increased early detection and advances in targeted therapy and immunotherapy combined. Instead, we compare hospitals suited to your cancer type, stage, budget, and language within the written opinion, and the final choice remains yours.

How Is Surgical Eligibility Determined by Stage?

Surgical eligibility is primarily determined by whether mediastinal lymph node metastasis is present. In the TNM staging of non-small cell lung cancer, stages 1-2 mean the tumor is confined to the lung with no lymph node involvement or involvement limited to nodes near the lung, making surgery the standard treatment. Stage 3 is a more complex category where cancer has spread to mediastinal lymph nodes or invaded surrounding structures, requiring a combination of surgery, chemotherapy, and radiation therapy. Stage 4 means the cancer has spread to the opposite lung, brain, bones, liver, or other distant sites, and systemic therapy becomes the central treatment approach.

What Is the Sequence From Diagnostic Workup to Surgery?

• Step 1: Chest CT identifies suspicious lesions, and tissue is confirmed via bronchoscopy, CT-guided needle biopsy, or surgical biopsy.
• Step 2: PET-CT checks for lymph node and distant organ metastasis, while brain MRI checks for brain metastasis, together determining the stage.
• Step 3: If mediastinal lymph node metastasis is suspected, endobronchial ultrasound (EBUS) with direct needle sampling confirms it.
• Step 4: If surgery is being considered, pulmonary function tests and cardiac evaluation assess whether the patient can tolerate the operation.
• Step 5: For stage 1-2, thoracoscopic or robotic lobectomy is performed; if the tumor is very small and favorably located, sublimited (sublobar) resection may be an option. Depending on surgical pathology results and EGFR mutation or PD-L1 status, continuing with post-operative targeted therapy or immunotherapy is now part of the standard approach.

FAQ — How Long Is Recovery After Surgery?

After lung surgery, a chest tube is typically kept in place for several days to drain air and fluid, and incision pain, coughing, and shortness of breath are common. Because part of the lung has been removed, breathing capacity decreases somewhat, but recovery progresses over weeks to months through breathing exercises and walking. Follow-up after surgery involves repeated chest CT scans at set intervals, with closer monitoring typically during the first 2-3 years.

FAQ — Can We Use Test Results Obtained Locally?

If you already have results from your home country, they can generally be used as is. If biomarker test results are missing or incomplete, tissue slides or paraffin blocks can be sent to Korea for NGS testing, or testing can be done after arrival. The typical target length of stay is around 2 weeks for surgery, and the remote review (pre-arrival review) fee of KRW 1,000,000 (about US$730) is deducted from treatment costs once a treatment agreement is made.

Sources and Notes

• This article was prepared based on National Cancer Registration Statistics 2019-2023 (Central Cancer Registry, National Cancer Center Korea), SEER 2016-2022, the National Cancer Information Center, NCCN patient guidelines, robotic surgery notes, and frequently asked question notes.
• This content is intended for general medical information purposes only. Diagnosis, treatment methods, and outcomes may vary depending on individual condition. Accurate diagnosis and treatment decisions should always be made in consultation with medical professionals.